HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

Jul 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-07-13

Reporting Person: Quart Barry D (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-30	Common Stock	J	1529	$13.8975	Acquired	96721	Direct
2021-07-13	Common Stock	M	3645	—	Acquired	100366	Direct
2021-07-13	Common Stock	F	963	$13.48	Disposed	99403	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-13	Restricted Stock Units	$	M	3645	Disposed		Common Stock (3645)	Direct

Footnotes

F1: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2021.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

F4: The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).